AUTHOR INDEX

Andrews P. 129
Armstrong, D. A. J. 1

Bonner, D. P. 321
Buchwald, H. 93

Cayen, M. N. 157
Chiba, P. 111
Cline, M. J. 69
Cory, J. G. 111

Diana, G. D. 287

Elford, H. L. 239

Fitch, L. 93
Fujii, A. M. 221

Goldfarb, M. P. 205

Kim, D. H. 49
Kornalik, F. 353

Lione, A. 255

McKinlay, M. A. 287

Otto, M. J. 287

Pestka, S. 299

Rowland, M. 49

Swabb, E. A. 321
Sykes, R. B. 321

Tarnowski, S. J. 299

Van Arman, C. G. 1
van't Riet, B. 239
Varco, R. L. 93
Vatner, S. F. 221

Whitfield, J. F. 407

Youdale, T. 407

AUTHOR INDEX

Andrews P. 129
Armstrong, D. A. J. 1

Bonner, D. P. 321
Buchwald, H. 93

Cayen, M. N. 157
Chiba, P. 111
Cline, M. J. 69
Cory, J. G. 111

Diana, G. D. 287

Elford, H. L. 239

Fitch, L. 93
Fujii, A. M. 221

Goldfarb, M. P. 205

Kim, D. H. 49
Kornalik, F. 353

Lione, A. 255

McKinlay, M. A. 287

Otto, M. J. 287

Pestka, S. 299

Rowland, M. 49

Swabb, E. A. 321
Sykes, R. B. 321

Tarnowski, S. J. 299

Van Arman, C. G. 1
van't Riet, B. 239
Varco, R. L. 93
Vatner, S. F. 221

Whitfield, J. F. 407

Youdale, T. 407

SUBJECT INDEX

Acetaminophen structure 36
Acetanilide structure 36
Acifran 182
Acipimox 179, 180
Allometry 62–66
Aluminium
  absorption 257, 258
  anaemias 267
  analysis in samples 255–57
  antacids 271–73
  aspirins 273, 274
  chelation 271
  excretion 260, 261
  intoxication
    diagnosis 269, 270
    treatment 270, 271
  medications 274, 275
  mineral metabolism 266, 267
  osteodystrophy 265, 266
  parathyroid gland 267, 268
  parenteral 258
  plasma binding 258, 259
  reference materials 257
  renal function 268
  sucral fate 274
  toxicology 255–77
  vaccines 275, 276
Ancrod 363–65
  experimental uses 389, 390
Anion exchange resins, drug interactions 184, 185
Antibiotics, β-lactam 321–47 *see also* individual antibiotic groups
  development 323
  limitations 346
  structures of natural 322
Antihyperlipidaemic agents *see also* individual drugs
  anion-exchange resins 186–86
  half-lives 185
  interactions between 187, 188
  liver effects 188–91
  pharmacokinetics 157–91
Antimalarials
  structure 14
  synthetic 19
Antipyretics 1–39
  ancient 20, 21
  assay methods 4–10
  cat 9
  drug comparisons 6
  drug families 10–39 *see also* individual drugs
  guinea-pig 10
  man 4–6
  mode of action 1, 2
  monkey 9, 10
  mouse 9
  rabbit 8, 9
  rat 6–8
Antipyrene, volume of distribution 63
Anti-schistosomal activity 129–51
AraC in combination chemotherapy 121, 122
Arildone structure 290
Aroylarylalkanoic acids structures 31
Arylalkanoic acids 29, 30
N-Arylanthranilic acids 29
Aryloxyarylalkanoic acids 30, 31
Aspirin, U.S. deaths 24
Atherosclerosis
  partial ileal bypass 93–103
  surgical intervention 93–108
Autonomic control, myocardial contractility 221–35
Aztreonam pharmacokinetics–342

Batroxobin 365, 366
  experimental uses 389, 390
B cell malignancies
  c-*abl* in leukaemia 208, 209
  c-*myc* expression 205–8
  translocation breakpoints 206
Bezafibrate 176, 177
Blood coagulation
  physiology 353–61
  plasmatic system 357
  scheme 358
  and snake venom enzymes 361–97
Botrocetin, platelet effects 381

Cancer, non-viral oncogenes 205–15
Carbapenem
  microbiology 334–38
  pharmacology 337, 338
  structures 335
Ceftazidime, serum pharmacokinetics 331
Cephalosporins 328–31
  microbiology 328–30
  pharmacology 320, 321
  structure and development 329
Cephalosporins 331–34
  microbiology 331–33
  pharmacology 333, 334
  structural development 332
Chinchophen 22
Chinoin-123 180
Chloroquine structure 20
Ciprofibrate 178, 179
Clofibrate 158–70
  absorption 159
  analysis 158
  biotransformation 166–68
  blood levels 159–61
  congeners 176–9
  distribution 165, 166
  drug interactions 164, 165
  drug metabolism 170
  kidney disease 168–70
  liver disease 168–70
  protein binding 162–64
  salts and prodrugs 161, 162
Clofibric acid 161
Clotting factors 356

Combination chemotherapy
nucleoside diphosphate reductase inhibition 249
ribonucleotide reductase target 111–14
Convulxin, platelet effects 378, 379
Crotalase 366, 367
Cytosine arabinoside, combination chemotherapy 120–24

Dantrolene sodium structure 29
Deoxyadenine, nucleoside diphosphate reductase 117–19
4′-6′-Dichloroflavan structure 295
γ-Dichroine 20–22
Diketone moiety, antiviral activity 287, 288
Distribution, physiologic modelling 51–54

Ecarin
experimental uses 390–92
prothrombin assay 392
Elimination, physiologic monitoring 54–59
Enolic acids, structures of antipyretics 27, 28
Epinephrine and myocardial contractility 227–29
Exercise and myocardial contractility 224–26

Febrifugine 20, 21
Fenofibrate 177, 178
biotransformation 177
Fever and prostaglandins 2
Fibrinogen
lysis by plasmin 361
structure 360
Fibrogenases 370–72
properties 370, 371
snake venom 371
Fluoropyrimidines in combination chemotherapy 120–23
FX, snake venom effects 376–78

Gemfibrozil 179
Gene insertion techniques 70
chromosome 71–74
microinjection 80, 81
Genes, c-*ras* transforming 211–14
Gene therapy 69–88
human disease 84–88
Gene transfer
cell proliferation 69
expression 73, 74
principles 69, 70
regulation 73, 74
retroviral vectors 74–80
techniques 71–73
Genetic transformation, haematopoietic cells 81–84

Haematopoietic cells
genetic transformation 81–84
retroviral vectors 83, 84
transfection 82, 83
Haemorrhage
heart epinephrine 230
and myocardial contractility 226
Hepatic clearance modelling 56–58
High performance chromatography, protein purification 300–302

Hydroxybenzohydroxamic acids and compounds
antineoplastic effects 248–51
antitumour actions 240–43
combination chemotherapy 249–51
DNA pool sizes 247, 248
dopa-like 245, 246
iron complexes 244
mechanism of action 243–45
mushroom cytobiotic factors 246, 247
nucleoside diphosphate reductase inhibition 239–52
structural features 240–43
synergism in leukaemia 250, 251
Hyperlipidaemias
lipid ratios 106, 107
POSCH trial 105–107
surgical control 104–107
changes 105, 106
treatment 107

Imipenem pharmacokinetics 337
Immunoaffinity chromatography 309–12
automated 311, 312
features 312, 313
large scale 310, 311
Indanecarboxylic acids 31
Indoleacetic acids 32
Indomethacin structure 32
Inhibitors
DNA polymerase 119, 120
dihydroxypeptidase 336
β-lactamase 343–45
nucleoside diphosphate reductase 114–19, 239–52
picornavirus uncoating 287–96
Interferon purification 299–316
animal 316
human fibroblast 313–15
human leucocyte 299–307
amino acid sequences 306, 307
carbohydrate 307
HPLC 300–303
multiple species 305
immune, IFN-γ 315
recombinant human leucocyte 307–13
immunoaffinity chromatography 309–12
immunosorbent 308
scheme 307
specific activities 304

β-Lactamase inhibition 343–45
microbiology 343–45
pharmacology 345
structures 344
Leukaemia, c-*abl* expression 208, 209
Liver, antihyperlipidaemic effects 188–91

Malaria 12–14
drug resistance 15
pyrogenic blood 13
red cell lysis 16
α-Melanocyte-stimulating hormone (α-MSH), antipyretic 38, 39
Methotrexate
dose–body weight 65
half-life and body weight 64
Mifobate 182

Modelling *see also* physiologic
physiologically based perfusion 59
recirculation 61
Monobactams
microbiology 338–41
pharmacology 341–3
structures of natural 340, 341
Muscle wasting 3
Myeloma, c-*mos* activation 210, 211
Myocardial contractility 221–35
arterial baroreflex 222, 223
catecholamines 227–29
chemoreflex 223, 224
denervation 233–35
exercise 224–26
haemorrhage 226
parasympathetic control 222
receptor blockades and drugs 234
sympathetic control 221, 222
sympathetic–parasympathetic interaction 229–33

Neomycin and antihyperlipidaemic agents 186
Nicotinic acid 170–76
analogues 179–81
analysis and absorption 171
biotransformation 175, 176
blood levels 171–74
distribution 174
drugs liberating 173
Norepinephrine
arterial pressure 231
autonomic blockade on heart 232
and myocardial contractility 228
Nucleoside diphosphate reductase
DNA polymerase 112, 113
inhibitors 114–16, 239–52
combination 116–19
properties 114
reaction catalysed 112
reduction 111–24

Oncogenes
c-*onc* amplification 209, 210
non-viral cancer role 205–15
Oxacephems 331–34
microbiology 331–33
pharmacology 333, 334
structural development 332
Oxazolopyridines, structures of antipyretics 35, 36

Pamaquine structure 19
Partial ileal bypass 93–108
angina changes 101
animal experiments 93–95
arteriography 101–103
complications 97
effect on cholesterol 94, 99
hyperlipidaemia 104
lipid changes 98
lipid metabolism 99, 100
postoperative observations 100, 101
side effects 97, 98
technique 95, 96
Penicillins
microbiology 324–26
pharmacology 326, 327
structural development 325
Phenacetin structure 36

Phospholipase A_2
anticoagulant 384, 385
platelet effects 381–84
Physiologic modelling
distribution 51–54
elimination 54–59
hepatic 56–58
renal 58, 59
integrated 59–61
pharmacokinetic 49–66
examples 60
scheme 50
tissue events 50–59
Picornavirus uncoating inhibitors 287–96
carbon bridge 289
diketone moiety 287, 288
in vitro 291, 292
in vivo 292, 293
mode of action 293
structures 289–91
Piperacillin pharmacokinetics 327
Platelet activation
scheme 355
snake venom effects 378–84
Polycycloaromatic alkanoic acids structures 33, 34
Praziquantel 129–51
assay methods 130
carbohydrate metabolism 144
cestode effects 146
conformation 129
efficacy 134
enzyme effects 145
fate of parasite 148–51
mammalian effects 147
mechanism of action 136–48
metabolic scheme 132
muscular contraction 137, 138
oral and serum levels 132
pharmacokinetics 130–36
primary effects 139–43
Schistosoma infection 134
secondary effects 143–48
tegument effects 138, 139
trematode effects 146
uptake and calcium 135
Primaquine 20
Probucol 181, 182
structure 181
Prostaglandin, antiinflammatory drugs 37
Protein, *ras* comparison 212
Prothrombin
ecarin activation 374
snake venom action 372–76
structure 359
Pyridinol carbamate 180, 181

Quinghaosin structure 23
Quinine
antipyretic 10–23
malaria effects 17
structures 11
Quinidine structure 11
Quinolines
antipyretic 10–23
ring 17–23
substituted, properties 18

Renal clearance, physiologic modelling 58, 59
Reptilase-R, diagnostic uses 388, 389

Retroviral vectors 74
  design 78–80
  genes inserted 78
  genome 75, 76
  model 77
  production 76, 77
Ribonucleotide reductase
  calf thymus 409
  E. coli and mammalian 407–18
    comparison criteria 409
  M1 component 412, 413
  rat liver cell 411
  structure 408
  synthesis burst 415
  synthesis, M1 and M2 414–16
Russel's viper venom, diagnostic uses 386–88

Salicylates *see also* aspirin
  antipyretics 23–27
  structures 25–27
Schistosomes
  drug uptake 136
  praziquantel effects 138–48
β-Sitosterol 186
Snake venom enzymes *see also* individual compounds
  anticoagulant action 384–86, 393
  blood coagulation 361–97
  clinical uses 392–97
  defibrinating effects 393–95
  diagnostic uses 386–92
  fibrinogen 363–72
  fibrinogenases 370–72
  FX effects 376–78
  platelet effects 378–84
  procoagulant hemostasis 395–97
  prothrombin action 372–76
  species producing 364
  thrombic proteases 364–69
Species scaling 62–66
Sphaeroplast fusion 72
Steroids, antipyretic 37, 38

Tetrahydroquinolines structure 18, 19
Thalassemia
  bone marrow transfection 85
  gene therapy 85
  HSV tk sequence 86, 87
Thrombic proteases 364–69
  properties 368, 369
Thrombocytin, platelet effects 380, 381
Tolbutamide, extraction ratio 55
Transfection 71, 72
Translocation, c-*myc* 207, 208

WIN 51711, mechanism of action 293, 294